AADI - Dividend announcements

-FYARRO™ approved November 22, 2021 and launched February 23, 2022- -FYARRO added to NCCN® Guidelines as the only preferred therapy to treat malignant PEComa- -PRECISION 1 tumor agnostic study for TSC1 or TSC2 alterations open for enrollment--Ended fourth quarter 2021 with $149.0 million in cash and cash equivalents- LOS ANGELES, March 17, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. ("Aadi") (NASDAQ:AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a business up

FYARRO™ under review with FDA with a November 26, 2021 PDUFA target dateThree key executive appointments made to the roles of Chief Operating Officer, Chief Medical Officer and Chief Financial OfficerAppointment of new board memberRegistrational trial in patients harboring TSC1 and TSC2 inactivating alterations expected to be initiated by the end of 2021 or early 2022Ended third quarter 2021 with $161.4 million in cash and cash equivalents with expected cash runway into 2024 following merger with Aerpio Pharmaceuticals, Inc. and concurrent PIPE financing LOS ANGELES, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. ("Aadi") (NASDAQ:AADI), a clinical-stage biopharmaceutical co